DPP-4 Inhibition and TZD for DM Prevention
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 5/27/2013 |
| Start Date: | July 2011 |
| End Date: | December 2012 |
| Contact: | Grace Jama-Adan, MPH |
| Email: | gjamaad@emory.edu |
| Phone: | 404-778-1688 |
DPP-4 Inhibition and Thiazolidinedione for Diabetes Mellitus Prevention (DInT DM Study)
To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or
without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and
insulin response individuals with impaired glucose tolerance (IGT), a form of prediabetes.
Inclusion Criteria:
- Impaired glucose tolerance (IGT) by oral glucose tolerance test
Exclusion Criteria:
- History of diabetes mellitus
- History of congestive heart failure
- History of coronary artery disease or other macrovascular disease (stroke, peripheral
vascular disease)
- History of liver disease (ALT or AST >2.5 times the upper limit of normals)
- History of renal disease (serum creatinine >1.5 mg/dl)
- History of severe osteoporosis (frequent fractures, failure on osteoporosis
treatment)
- Current treatment with glucocorticoids
- History of immune disorder, including HIV
- Women of child-bearing age who are pregnant, desire to become pregnant, are
breastfeeding, or who refuse to take the recommended birth control measures
We found this trial at
2
sites
Emory University Hospital As the largest health care system in Georgia and the only health...
Click here to add this to my saved trials
Grady Memorial Hospital Grady is an internationally recognized teaching hospital staffed exclusively by doctors from...
Click here to add this to my saved trials